In addition, both preclinical and clinal trials indicated that targeting CXCR2 and CXCR4 increased the efficacy of immunotherapy by reducing tumor neutrophil infiltration and promoting adaptive immune responses. The gene discussed is CXCR2; the disease is neoplasm.